8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


        Date of Report (Date of earliest event reported) March 31, 2011
                                                         --------------

                             REPRO-MED SYSTEMS, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


          NEW YORK                       0-12305                 13-3044880
----------------------------           ------------          -------------------
(State or other jurisdiction           (Commission             (IRS Employer
      of incorporation)                File Number)          Identification No.)


               24 Carpenter Road, Chester, New York            10918
             ----------------------------------------        ----------
             (Address of principal executive offices)        (Zip Code)


        Registrant's telephone number, including area code (845) 469-2042
                                                           --------------

                                 not applicable
         --------------------------------------------------------------
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))



ITEM 8.01 OTHER EVENTS.

The Company issued a press release announcing the Company's unaudited financial
results for its fiscal year ended February 28, 2011. The press release titled
"REPRO-MED SYSTEMS, INC., REPORTS 30% INCREASE IN REVENUE FOR FISCAL YEAR ENDED
FEBRUARY 28, 2011" is furnished herewith as Exhibit 99.1.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

Exhibit   Description
-------   -----------

99.1      Press release dated March 31, 2011.


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                       REPRO-MED SYSTEMS, INC.
                                       (Registrant)


Date  March 31, 2011                   By: /s/ Andrew I. Sealfon
      --------------                       ---------------------
                                           Andrew I. Sealfon
                                           President and Chief Executive Officer

                                     - 2 -

EX-99

                                  EXHIBIT 99.1

REPRO-MED SYSTEMS, INC., REPORTS 30% INCREASE IN REVENUE FOR FISCAL YEAR ENDED
FEBRUARY 28, 2011

Chester, New York - March 31, 2011 - (PR NEWSWIRE) -- Repro-Med Systems Inc,
(REPR) dba RMS Medical Products, today announced unaudited financial results for
its fiscal year ended February 28, 2011, showing increases in both domestic and
international sales.

The medical devices company is the manufacturer of the FREEDOM60(R) Syringe
Infusion System and the RES-Q-VAC(R) emergency hand held suction system. The
company also produces expendables used in conjunction with those devices.

Andrew Sealfon, President and CEO of Repro-Med Systems, Inc., stated, "This is
the strongest year since inception, with more than $4.9 million in sales
revenue. In addition, the fourth quarter of fiscal year 2011 saw revenues in
excess of $1.6 million and continues our positive progress for the fourth,
consecutive year."

Financial highlights for the fiscal year ending February 28, 2011 include:

   o  Overall Net Revenue increased by 30%;

   o  FREEDOM60(R) Syringe Infusion System overall product line revenue
      increased by 38%;

   o  FREEDOM60(R) Syringe Infusion System international revenue increased by
      83%;

   o  Strongest sales quarter (fourth quarter ending February 28, 2011) and year
      in the company's 30-year history.

Mr. Sealfon noted, "We are pleased with the progress we have made in the past
year and are looking for continued growth for the coming year, especially with
new subcutaneous medications reaching the market served by our FREEDOM60(R)."

About the principal devices manufactured by Repro-Med Systems
(www.rmsmedpro.com):
-------------------------------------------------------------

A primary use for the FREEDOM60(R) Syringe Infusion Pump is in subcutaneous
administration of immune globulin due to its safe, controlled pressure and
ability to adjust automatically to the flow. The inherently safe pressures used
to deliver drugs to patients minimize discomfort, swelling and other
complications sometimes found with conventional electric infusion devices. There
are additional applications such as the delivery of antibiotics for the
ambulatory patient.

RES-Q-VAC(R) is a hand operated suction system that fills a niche in emergency
medicine, hospitals, and home care for immediate airway suction when and
wherever needed. RES-Q-VAC(R) has patented filtration to minimize exposure of
medical personnel to dangerous pathogens from patients infected with life
threatening diseases such as tuberculosis and SARS. Because RES-Q-VAC(R)
provides reliable suction without power, it is useful in disasters when the
electricity fails.



Forward Looking Statements

Statements in this press release may contain "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, may be forward-looking
statements. These statements are based on management's current expectations and
are subject to uncertainty and changes in circumstances. These statements
involve risks and uncertainties that could cause actual results to differ
materially from those included in forward-looking statements due to a variety of
factors. More information about these factors can be found in Repro-Med's latest
Annual Report filed with Securities and Exchange Commission on Form 10-K. The
company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

                                      ###